Olodaterol attenuates bleomycin induced lung fibrosis in mice

Franziska Herrmann (Biberach an der Riss, Germany), Franziska Herrmann, Stefan-Lutz Wollin, Florian Gantner, Eva Wex

Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Session: Airway pharmacology: drug targets and mode of action
Session type: Poster Discussion
Number: 5056
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Franziska Herrmann (Biberach an der Riss, Germany), Franziska Herrmann, Stefan-Lutz Wollin, Florian Gantner, Eva Wex. Olodaterol attenuates bleomycin induced lung fibrosis in mice. Eur Respir J 2016; 48: Suppl. 60, 5056

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013


A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013

Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016


Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015

Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016

PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013


Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015

17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013


The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013


Does Rosemary leaves extract can attenuate lung injury in experimental pulmonary fibrosis in rats?
Source: International Congress 2016 – ILD pathogenesis
Year: 2016


17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015


PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013


Thymosin beta4 protects mice from bleomycin-induced damage in the lung
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013

Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016


Influenza infection affects the degree of fibrosis and apoptosis in the bleomycin mouse model
Source: Annual Congress 2013 –Interesting research questions
Year: 2013

Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016


New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015

Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice
Source: Eur Respir J 2005; 25: 708-714
Year: 2005



Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013